Neuropeptides in the human intra - and extracerebral circulation - before and after affecting the trigeminovascular system with sumatriptan in healthy volunteers. - Neuropeptidstudy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-002677-41-DK

Enrollment

Registered

2006-06-30

Start date

2006-07-21

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteers

Interventions

Product Name: Sumatriptan Pharmaceutical Form: Injection*

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: healthy non-pregnant volunteers without any serious medical conditions. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: pregnancy. Serious medical conditions. Allergy to sumatriptan.

Design outcomes

Primary

Measure	Time frame
Main Objective: measure the concentration of neuropeptides in the human circulation before and after the application of sumatriptan.;Secondary Objective: ;Primary end point(s): changes in concentration of neuropeptides in the human circulation.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026